Inspired by the current studies on the effective efficacy of CD229-based CAR-T therapy, we herein examined the expression of CD229 in a subpopulation of myeloma, and demonstrated the role of CD229 in promoting MM cell proliferation through the underlying mechanism of CD229-mediated RAS/ERK signaling. Here, LY9 is linked to plasma cell myeloma.